Srividya Swaminathan
Research Subjects
Srividya Swaminathan has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Ramasamy Karvembu
National Institute of Technology
4 shared publications - Jebiti Haribabu
Facultad de Medicina, Universidad de Atacama, Los Carreras 1579, 1532502 Copiapo, Chile
3 shared publications - Nithya Balakrishnan
Department of Chemistry National Institute of Technology Tiruchirappalli India
3 shared publications Jebiti Haribabu
Facultad de Medicina Universidad de Atacama Copiapó Chile
2 shared publications- Arunachalam Arulraj
Departamento de Electricidad, Facultad de Ingeniería, Universidad Tecnológica Metropolitana, Av. José Pedro Alessandri 1242, Ñuñoa 7800002, Santiago, Chile
1 shared publication Daniel Moraga
Laboratorio de Fisiología, Departamento de Ciencias Biomédicas, Facultad de Medicina Universidad de Tarapacá Arica Chile
1 shared publication
Latest Publications
- 1 January 2025
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 39 (9)
Optimizing Nickel Complex With Thiosemicarbazone for Viral (SARS‐CoV‐2) Applications and Cancer Therapy: Synthesis, DFT Calculations, Molecular Docking, Molecular Dynamics Simulations, and Anticancer Activity
This study delves into the synthesis, characterization, and biological evaluation of novel nickel(II) complex with isatin‐based thiosemicarbazone (TSC), aimed at exploring their potential in cancer therapy. Employing a blend of experimental methodologies and computational tools, including density functional theory (DFT) calculations, molecular docking, and dynamics simulation, we investigated the stability, electronic properties, and biological effects of these compounds. Analysis via spectroscopy validated successful synthesis, offering insights into their structural characteristics, while X‐ray diffraction analysis affirmed their crystalline structure. DFT calculations were utilized to assess electronic structure optimization, HOMO‐LUMO energy gaps, and global parameters, with molecular modeling revealing bond angles, bond lengths, and pertinent quantum chemical factors using the DFT method. Additionally, molecular docking and MD simulations were conducted to forecast binding modes and interactions between the ligands and the SARS‐CoV‐2 main protease (MPro). Computational findings underscored advantageous electronic structures and potential reactivity, supported by molecular docking studies showing robust binding affinities towards vital biological targets such as the SARS‐CoV‐2 main protease, human ACE‐2 enzyme, and VEGFR2. Furthermore, the anticancer potential of these compounds was assessed via in vitro assays on diverse cancer cell lines, unveiling selective cytotoxicity, and encouraging therapeutic prospects.
- 1 January 2025
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 39 (9)
Optimizing Nickel Complex With Thiosemicarbazone for Viral (SARS‐CoV‐2) Applications and Cancer Therapy: Synthesis, DFT Calculations, Molecular Docking, Molecular Dynamics Simulations, and Anticancer Activity
This study delves into the synthesis, characterization, and biological evaluation of novel nickel(II) complex with isatin‐based thiosemicarbazone (TSC), aimed at exploring their potential in cancer therapy. Employing a blend of experimental methodologies and computational tools, including density functional theory (DFT) calculations, molecular docking, and dynamics simulation, we investigated the stability, electronic properties, and biological effects of these compounds. Analysis via spectroscopy validated successful synthesis, offering insights into their structural characteristics, while X‐ray diffraction analysis affirmed their crystalline structure. DFT calculations were utilized to assess electronic structure optimization, HOMO‐LUMO energy gaps, and global parameters, with molecular modeling revealing bond angles, bond lengths, and pertinent quantum chemical factors using the DFT method. Additionally, molecular docking and MD simulations were conducted to forecast binding modes and interactions between the ligands and the SARS‐CoV‐2 main protease (MPro). Computational findings underscored advantageous electronic structures and potential reactivity, supported by molecular docking studies showing robust binding affinities towards vital biological targets such as the SARS‐CoV‐2 main protease, human ACE‐2 enzyme, and VEGFR2. Furthermore, the anticancer potential of these compounds was assessed via in vitro assays on diverse cancer cell lines, unveiling selective cytotoxicity, and encouraging therapeutic prospects.
- 7 October 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (23) , e202400435
From Concept to Cure: The Road Ahead for Ruthenium‐Based Anticancer Drugs
The evolution of chemotherapy, especially the dawn of metal‐based drugs, represents a transformative era in cancer treatment. From the serendipitous discovery of mustard gas's cytotoxic effects to the sophisticated development of targeted therapies, chemotherapy has significantly refined. Central to this progression is the incorporation of metal‐based compounds, such as platinum (Pt), ruthenium (Ru), and gold (Au), which offer unique mechanisms of action, distinguishing them from organic therapeutics. Among these, Ru complexes, exemplified by BOLD‐100 and TLD1433, have shown exceptional promise due to their selective activity, lower propensity for resistance, and the ability to target spescific cellular pathways. This paper explores the journey of such Ru candidates, focusing on the mechanisms, efficacy, and clinical potential of these Ru‐based drugs, which stand at the forefront of current research, aiming to provide more targeted, less toxic, and highly effective cancer treatments.
- 7 October 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (23) , e202400435
From Concept to Cure: The Road Ahead for Ruthenium‐Based Anticancer Drugs
The evolution of chemotherapy, especially the dawn of metal‐based drugs, represents a transformative era in cancer treatment. From the serendipitous discovery of mustard gas's cytotoxic effects to the sophisticated development of targeted therapies, chemotherapy has significantly refined. Central to this progression is the incorporation of metal‐based compounds, such as platinum (Pt), ruthenium (Ru), and gold (Au), which offer unique mechanisms of action, distinguishing them from organic therapeutics. Among these, Ru complexes, exemplified by BOLD‐100 and TLD1433, have shown exceptional promise due to their selective activity, lower propensity for resistance, and the ability to target spescific cellular pathways. This paper explores the journey of such Ru candidates, focusing on the mechanisms, efficacy, and clinical potential of these Ru‐based drugs, which stand at the forefront of current research, aiming to provide more targeted, less toxic, and highly effective cancer treatments.
- 7 January 2024
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 503
Platinum group metal (PGM) complexes having acylthiourea ligand system as catalysts or anticancer agents
- 7 January 2024
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 503
Platinum group metal (PGM) complexes having acylthiourea ligand system as catalysts or anticancer agents
- 6 June 2022
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (7)
Impact of denticity of chromone/chromene thiosemicarbazones in the ruthenium(II)‐DMSO complexes on their cytotoxicity against breast cancer cells
Denticity plays a prominent role in the cytotoxicity of metal complexes. The impact of ligand denticity of chromone/chromene thiosemicarbazones (TSCs) in the Ru(II)‐DMSO complexes on the cytotoxicity of cancer cells was evaluated. Ru(II)‐DMSO complex containing tridentate chromone TSC (D1) exhibited better in vitro anticancer activity than the one with bidentate chromene TSC (D2). Using the optimized structures of the complexes, the reason behind the same was attributed to the thermodynamically stable nature of the tridentate system. Hydrolysis study of the complexes showed the kinetically labile nature of the chloride ligand in the tridentate species with respect to the bidentate counterpart. The selective cytotoxicity of complex D1 against breast cancer cells and its less toxicity against normal cells demonstrated the effective anticancer potential of the complex. Further, the binding efficacy of the complexes against DNA and BSA, along with imaging and flow cytometry experiments, warranted the effective cell death induced by the complexes against breast cancer cells via apoptosis.
- 6 June 2022
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (7)
Impact of denticity of chromone/chromene thiosemicarbazones in the ruthenium(II)‐DMSO complexes on their cytotoxicity against breast cancer cells
Denticity plays a prominent role in the cytotoxicity of metal complexes. The impact of ligand denticity of chromone/chromene thiosemicarbazones (TSCs) in the Ru(II)‐DMSO complexes on the cytotoxicity of cancer cells was evaluated. Ru(II)‐DMSO complex containing tridentate chromone TSC (D1) exhibited better in vitro anticancer activity than the one with bidentate chromene TSC (D2). Using the optimized structures of the complexes, the reason behind the same was attributed to the thermodynamically stable nature of the tridentate system. Hydrolysis study of the complexes showed the kinetically labile nature of the chloride ligand in the tridentate species with respect to the bidentate counterpart. The selective cytotoxicity of complex D1 against breast cancer cells and its less toxicity against normal cells demonstrated the effective anticancer potential of the complex. Further, the binding efficacy of the complexes against DNA and BSA, along with imaging and flow cytometry experiments, warranted the effective cell death induced by the complexes against breast cancer cells via apoptosis.
- 6 January 2021
- Published by Wiley in Chemistry – A European Journal
- Vol. 27 (26) , 7418-7433
Tunable Anticancer Activity of Furoylthiourea‐Based RuII–Arene Complexes and Their Mechanism of Action
Fourteen new RuII–arene (p‐cymene/benzene) complexes (C1–C14) have been synthesized by varying the N‐terminal substituent in the furoylthiourea ligand and satisfactorily characterized by using analytical and spectroscopic techniques. Electrostatic potential maps predicted that the electronic effect of the substituents was mostly localized, with some influence seen on the labile chloride ligands. The structure–activity relationships of the Ru–p‐cymene and Ru–benzene complexes showed opposite trends. All the complexes were found to be highly toxic towards IMR‐32 cancer cells, with C5 (Ru–p‐cymene complex containing C6H2(CH3)3 as N‐terminal substituent) and C13 (Ru–benzene complex containing C6H4(CF3) as N‐terminal substituent) showing the highest activity among each set of complexes, and hence they were chosen for further study. These complexes showed different behavior in aqueous solutions, and were also found to catalytically oxidize glutathione. They also promoted cell death by apoptosis and cell cycle arrest. Furthermore, the complexes showed good binding ability with the receptors Pim‐1 kinase and vascular endothelial growth factor receptor 2, commonly overexpressed in cancer cells.
- 6 January 2021
- Published by Wiley in Chemistry – A European Journal
- Vol. 27 (26) , 7418-7433
Tunable Anticancer Activity of Furoylthiourea‐Based RuII–Arene Complexes and Their Mechanism of Action
Fourteen new RuII–arene (p‐cymene/benzene) complexes (C1–C14) have been synthesized by varying the N‐terminal substituent in the furoylthiourea ligand and satisfactorily characterized by using analytical and spectroscopic techniques. Electrostatic potential maps predicted that the electronic effect of the substituents was mostly localized, with some influence seen on the labile chloride ligands. The structure–activity relationships of the Ru–p‐cymene and Ru–benzene complexes showed opposite trends. All the complexes were found to be highly toxic towards IMR‐32 cancer cells, with C5 (Ru–p‐cymene complex containing C6H2(CH3)3 as N‐terminal substituent) and C13 (Ru–benzene complex containing C6H4(CF3) as N‐terminal substituent) showing the highest activity among each set of complexes, and hence they were chosen for further study. These complexes showed different behavior in aqueous solutions, and were also found to catalytically oxidize glutathione. They also promoted cell death by apoptosis and cell cycle arrest. Furthermore, the complexes showed good binding ability with the receptors Pim‐1 kinase and vascular endothelial growth factor receptor 2, commonly overexpressed in cancer cells.